Antibody (1)
Launched (1)
Mouse (1)
- (1)
Unconjugated (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
NO1-MY2228 | HEK293 | Monoclonal Anti-Human NoV(GII.13)VP1 Antibody, Mouse IgG1 (2B10) (MALS verified) |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| SHR-9146 | HTI-1090; SHR-9146 | Phase 1 Clinical | Solid tumours; Neoplasms | Details | |
| LPM-3480226 | LY-01013; LPM-3480226 | Phase 1 Clinical | Luye Pharma Group Ltd | Solid tumours | Details |
| DN-1406131 | DN-131; DN-1406131 | Phase 1 Clinical | Jiangxi Qingfeng Pharmaceutical Industry Co Ltd, Shanghai De Novo Pharmatech Co Ltd | Solid tumours; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



